1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester is a complex organic molecule that is likely being researched for its potential pharmaceutical applications. Here's why:
* **Structural features:** The compound combines elements of several important chemical classes:
* **Indole:** Indoles are a core structure found in numerous biologically active molecules, including the neurotransmitter serotonin.
* **Carboxylic acid:** The carboxylic acid group is often involved in interactions with proteins and enzymes.
* **Quinoline:** Quinoline derivatives are known for their diverse biological activity, including antimalarial and antibacterial properties.
* **Potential for drug discovery:** The combination of these structural features suggests that 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester might possess pharmacological activity.
* **Research avenues:** Researchers might be investigating this compound for various reasons:
* **Target identification:** They could be trying to identify the specific biological targets (proteins, enzymes) that this compound interacts with.
* **Pharmacological activity:** They may be evaluating the compound's potential for treating diseases related to serotonin function or other areas where quinoline derivatives are known to be active.
* **Structure-activity relationships:** Researchers could be modifying the structure of this compound to optimize its biological activity and potentially develop new drug candidates.
**Important Note:** The research on this specific compound is likely ongoing, and detailed information about its activity and importance might not be publicly available.
If you are interested in learning more about this compound, you could try searching scientific databases like PubMed or Google Scholar using the full chemical name or its potential synonyms.
1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester: a recreational synthetic cannabinoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71604304 |
| SCHEMBL ID | 16201696 |
| MeSH ID | M000597041 |
| Synonym |
|---|
| pb 22 |
| quinolin-8-yl 1-pentylindole-3-carboxylate |
| CS-1405 |
| pb-22 |
| 1400742-17-7 |
| quinolin-8-yl 1-pentyl-1h-indole-3-carboxylate |
| HY-13712 |
| AKOS022172960 |
| 1h-indole-3-carboxylic acid, 1-pentyl-, 8-quinolinyl ester |
| qm6j8f29fe , |
| unii-qm6j8f29fe |
| dea no. 7222 |
| qupic |
| 1-pentyl-1h-indole-3-carboxylic acid 8-quinolinyl ester |
| j3.283.188e , |
| pb-22 (cannabinoid) |
| FT-0697640 |
| SCHEMBL16201696 |
| DTXSID70856177 |
| NCGC00390698-01 |
| Q15708309 |
| 1-pentyl-1h-indole-3-carboxylicacid8-quinolinylester |
| pb-22 solution |
| CP175130 |
| pb-22 (crm) |
| pb-22, 0.1mg/ml in acetonitrile |
| pb-22, 1mg/ml in acetonitrile |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 4.2534 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 3.3786 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||